Cellectis develops allogeneic CAR-T cell product candidates including lasme-cel targeting CD22 for B-cell acute lymphoblastic leukemia in Phase 1 (BALLI-01), eti-cel targeting CD20 and CD22 for non-Hodgkin lymphoma in Phase 1 (NatHaLi-01), cema-cel targeting CD19 for large B-cell lymphoma in Phase 1 (ALPHA3) licensed to Servier and Allogene, ALLO-316 targeting CD70 for renal cell carcinoma in Phase 1 (TRAVERSE) licensed to Allogene, and IOV-4001 tumor-infiltrating lymphocytes for melanoma in Phase 1. These therapies serve patients with hematological malignancies and solid tumors through off-the-shelf treatments derived from healthy donor T-cells. The company uses TALEN gene-editing technology for precise T-cell modifications and the PulseAgile electroporation system. Founded in 1999 by André Choulika, Ph.D. (CEO since inception) and David Sourdive, Ph.D. (Executive Vice President CMC & Manufacturing since 2000). Cellectis maintains headquarters in Paris, France, with offices in New York, New York, and a manufacturing facility in Raleigh, North Carolina. The company is publicly traded on Nasdaq Global Market (CLLS) and Euronext Growth Paris (ALCLS), with collaborations including AstraZeneca.